RC48 in Combination With AK104 and Bevacizumab in OCCC

This trial is testing a combination of three treatments — RC48 (an antibody-drug conjugate targeting HER2), AK104 (an immunotherapy), and bevacizumab (a drug that stops tumors from growing new blood vessels) — for people with ovarian clear cell carcinoma, a rare and often treatment-resistant type of ovarian cancer. **You may be eligible if...** - Your pathology confirms ovarian clear cell carcinoma (or mixed with at least 70% clear cell component) - Your tumor shows HER2 protein expression (IHC score ≥ 1+) - You have at least one measurable tumor and have progressed during or after prior platinum-based chemotherapy (up to 2 prior lines of therapy) **You may NOT be eligible if...** - Your tumor does not express HER2 - You have had more than 2 prior lines of treatment - You have serious heart, liver, or kidney conditions that prevent you from receiving these drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.